Osimertinib has been shown to penetrate the blood–brain barrier in animal models (10) and has shown promising therapeutic efficacy in NSCLC–LM patients resistant to prior EGFR-TKI therapy (11). This evidence concerns the gene EGFR and non-small cell lung carcinoma.